Article
Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
Drug delivery - 1 Dec 2021
Li Xixi, Zhu Shunyao, Yin Ping, Zhang Shuangshuang, Xu Juewen, Zhang Qin, Shi Senlin, Zhang Ting
Abstract excerpt
Melanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35-40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been attempted. Herein, we assessed whether chlorogenic acid liposomes modified with sialic acid (CA-SAL) combined with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.